Completely revised and updated for 2013, the Physicians’ Cancer Chemotherapy Drug Manual 2013 is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers. Special features: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like brentuximab, carfilzomib, crizotinib, pertuzumab, rogorafenib, vemurafenib, and vismodegib. • A specific chapter focused on profiling antiemetic drug and antiemetic treatment regimens. • Diagrams of drug structures and pathways for many of the agents. • Offers a comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages. • Covers toxicity and drug–drug interactions. • A section on chemotherapy regimens for all major cancers. • Provides an overview of the basic principles of cancer drug therapy. • Contains an easy to load and use CD version. Mobile version of Physicians’ Cancer Chemotherapy Drug Manual also available!

Written by world-class experts in clinical cancer therapeutics, Physicians’ Cancer Chemotherapy Drug Manual 2019 provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers.

Completely revised and updated for 2023, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers.

Completely revised and updated for 2024, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers.

Written by world-class experts in clinical cancer therapeutics, Physicians’ Cancer Chemotherapy Drug Manual 2020 provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers.

Written by world-class experts in clinical cancer therapeutics, Physicians’ Cancer Chemotherapy Drug Manual 2018 provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers.

Includes free CD-ROM! Completely revised and updated for 2008, this practical handbook is an up-to-date guide to all aspects of cancer chemotherapy. The book provides a comprehensive, easy to use catalogue of over 100 drugs-both on- and off-label-commonly used in cancer treatment. A section on Common Chemotherapy Regimens provides a quick reference to management of specific cancers, arranged alphabetically. Special features include: Special chapter profiling anti-emetic drugs Diagrams of drug structures and pathways Complete discussion of clinical pharmacology, indications, and dosages Coverage of toxicity and interactions Separate chapter on chemotherapy regimens for specific cancers Overview of basic principles of cancer drug therapy Easy to load and use CD-ROM version PDA version of Physicians' Cancer Chemotherapy Drug Manual also available! * Correction to the 2008 edition of the Physicians’ Cancer Chemotherapy Drug Manual. On page 402, Capecitabine + Lapatinib is incorrectly listed as a Combination Regimen option for patients with Her2 negative mBC. As a correction, Capecitabine + Lapatinib should be listed as a Combination Regimen option for patients with Her2 postive mBC and removed from the listing for Her2 negative disease.